Product Description
Mechanisms of Action: V1 Agonist, V2 Agonist, V3 Agonist
Novel Mechanism: Yes
Modality: Large Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Australia | Brazil | Germany | Malta | New Zealand | Norway | Portugal | South Africa | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Taibah University
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|